Guizhou Yibai Pharmaceutical Co Ltd (600594) - Total Liabilities
Based on the latest financial reports, Guizhou Yibai Pharmaceutical Co Ltd (600594) has total liabilities worth CN¥1.16 Billion CNY (≈ $169.24 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Guizhou Yibai Pharmaceutical Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Guizhou Yibai Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Guizhou Yibai Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Guizhou Yibai Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guizhou Yibai Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Atrium Mortgage Investment Corp
TO:AI
|
Canada | CA$367.47 Million |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥1.50 Billion |
|
Costamare Bulkers Holdings Limited
NYSE:CMDB
|
USA | $309.79 Million |
|
Sappi Ltd
JSE:SAP
|
South Africa | ZAC3.63 Billion |
|
Burstone Group Limited
JSE:BTN
|
South Africa | ZAC9.09 Billion |
|
Guangdong Failong Crystal Technology Co Ltd
SHE:300460
|
China | CN¥980.04 Million |
|
NACL Industries Limited
NSE:NACLIND
|
India | Rs6.81 Billion |
|
Beijing Succeeder Technology Inc
SHG:688338
|
China | CN¥69.11 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Guizhou Yibai Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Guizhou Yibai Pharmaceutical Co Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guizhou Yibai Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guizhou Yibai Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Guizhou Yibai Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.17 Billion ≈ $171.39 Million |
-21.58% |
| 2024-12-31 | CN¥1.49 Billion ≈ $218.56 Million |
-5.41% |
| 2023-12-31 | CN¥1.58 Billion ≈ $231.06 Million |
-5.78% |
| 2022-12-31 | CN¥1.68 Billion ≈ $245.23 Million |
+11.31% |
| 2021-12-31 | CN¥1.51 Billion ≈ $220.31 Million |
-14.61% |
| 2020-12-31 | CN¥1.76 Billion ≈ $258.02 Million |
-6.95% |
| 2019-12-31 | CN¥1.89 Billion ≈ $277.29 Million |
-26.12% |
| 2018-12-31 | CN¥2.56 Billion ≈ $375.34 Million |
+0.47% |
| 2017-12-31 | CN¥2.55 Billion ≈ $373.58 Million |
+6.54% |
| 2016-12-31 | CN¥2.40 Billion ≈ $350.64 Million |
+17.60% |
| 2015-12-31 | CN¥2.04 Billion ≈ $298.16 Million |
-1.63% |
| 2014-12-31 | CN¥2.07 Billion ≈ $303.10 Million |
+63.30% |
| 2013-12-31 | CN¥1.27 Billion ≈ $185.61 Million |
+73.44% |
| 2012-12-31 | CN¥731.33 Million ≈ $107.02 Million |
+9.89% |
| 2011-12-31 | CN¥665.51 Million ≈ $97.38 Million |
-3.38% |
| 2010-12-31 | CN¥688.82 Million ≈ $100.80 Million |
+20.58% |
| 2009-12-31 | CN¥571.26 Million ≈ $83.59 Million |
-7.95% |
| 2008-12-31 | CN¥620.62 Million ≈ $90.82 Million |
+1.70% |
| 2007-12-31 | CN¥610.24 Million ≈ $89.30 Million |
+8.53% |
| 2006-12-31 | CN¥562.27 Million ≈ $82.28 Million |
-13.85% |
| 2005-12-31 | CN¥652.65 Million ≈ $95.50 Million |
+80.74% |
| 2004-12-31 | CN¥361.10 Million ≈ $52.84 Million |
+31.35% |
| 2003-12-31 | CN¥274.93 Million ≈ $40.23 Million |
+57.22% |
| 2002-12-31 | CN¥174.87 Million ≈ $25.59 Million |
+29.36% |
| 2001-12-31 | CN¥135.18 Million ≈ $19.78 Million |
-- |
About Guizhou Yibai Pharmaceutical Co Ltd
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatic bone, digestive system… Read more